drugset
drugset / Trial / NCT03491748

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants

NCT03491748 ↗

Phase 1 Completed 99 enrolled Entasis Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) and multiple ascending doses (MAD) of oral ETX0282 when administered alone and in combination with cefpodoxime proxetil in healthy adult participants.

Timeline

Start
2018-03-16
Primary completion
2019-09-11
Completion
2019-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefpodoxime proxetil Small molecule 400 mg Oral
Subject ETX0282 Unknown 75 mg Oral
Subject ETX0282 Unknown 100 mg Oral
Subject ETX0282 Unknown 200 mg Oral
Subject ETX0282 Unknown 300 mg Oral
Subject ETX0282 Unknown 400 mg Oral
Subject ETX0282 Unknown 600 mg Oral
Subject ETX0282 Unknown 800 mg Oral

Indications

No indication recorded.